Morgan Stanley Reiterates Overweight Rating on Jazz Pharmaceuticals plc (JAZZ)

Market Context

Jazz Pharmaceuticals plc operates in the Healthcare sector. The stock currently trades at $249.69 with a market capitalization of $10.0B. The stock has gained 79.2% over the past 52 weeks.

Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Jazz Pharmaceuticals plc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Jazz Pharmaceuticals plc

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 04, 2026	Wells Fargo	Overweight	N/A
Aug 04, 2026	Morgan Stanley	Overweight	N/A
Aug 04, 2026	Piper Sandler	Overweight	N/A
Aug 04, 2026	Barclays	Overweight	N/A
Aug 04, 2026	Needham	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View JAZZ Stock Page